Gyogyszerkutato Intezet Kft.

Schering Aktiengesellschaft

Egis Gyogyszergyar

Egis Gyogyszergyar Rt.

Gyogyszerkutato Intezet

Richter Gedeon Vegyeszeti Gyar Rt

Egyt Gyogyszervegyeszeti Gyar

Alkaloida Vegyeszeti Gyar

Biogal Gyogyszergyar

Ivax Drug Research Institute

Cyogyszerkutato Intezet Kft

Gis Gyogyszergyar Rt.

Gyogyszerkutato Intezet Kv.

Ferenc Andrasi

Pal Berzsenyi

Tamas Hamori

Imre Moravcsik

Katalin Goldschmidt

Istvan Tarnawa

Jeno Korosi

Peter Botka

Gabor Zolyomi

Antal Simay

Sandor Farkas

Istvan Elekes

Lajos Toldy

Laszlo Sebestyen

Zsuzsanna Fittler

Peter Matyus

Sandor Solyom

Istvan Ling

Marta Szollosy

Melinda Gal

Eszter Szentkuti

Istvan Sziraki

Eszter Hodula

Klara Sutka

Lajos Farkas

Valeria Vitkoczi

Katalin Horvath

Istvan Gyertyan

Jozsef Reiter

Tibor Lang

Istvan Polgari

Jozsef Borsi

Pal Vago

Katalin Eszter Horvath

Eva Gal

Agnes Papp

Erzsebet Zara

Anna Bakonyi

Gizella Abraham

Ildiko Mathe

Marta Rusz

Gyorgyne Mate

Edit Horvath

Tibor Hasko

Laszlo Szporny

Gyula Simig

Elemer Ezer

Gabor Gigler

Istvan Gacsalyi

Gyula Horvath

Gabor Blasko

Judit Matuz

Katalin Saghy

Peter Aranyi

Endre Kasztreiner

Sandor Elek

Zoltan Zubovics

Andras Egyed

Gyorgy Somogyi

Istvan Pallagi

Geza Schneider

Andras Bilkei-Gorzo

Sandor Boros

Karoly Tihanyi

Judit Bajnogel

Emese Csuzdi

Zsuzsanna Lang Nee Rihmer

Agnes Papp Nee Behr

Ernese Csuzdi

Endre Tihanyi

Arpad Lazar

Eleonora Sineger

Ildiko Varga

Laszlo Gabor Harsing

Eva Tomori Nee Joszt

Katalin Goldschmidt Nee Horvath

Marta Rusz Nee Patfalusi

Katalin Szilagyi

Katalin Gorgenyi

Jozsef Gyimesi

Franciska Erdo

Emese Csuzdl

Gabor Kapus

Erzsebet Birkas

Erszebet Birkas

Cecilia Salamon Haskane

Peter Korosi

Peter Botka, Deceased

Hilda Botka

Klara Daroczi Kazone

Jeno Korosi, Deceased

Katalin G Horvath

Zsuzsanna L Rihmer

Agnes Angyal Nee Pataky

Erzsebet F Birkas

Erno Koltai

Erzsebet Szabo Nee Bagdy

Katalin Szabo Nee Pusztai

Pyridazino(4,5-b)(1,5)oxazepinone, -thiazepinone and -diazepinone compounds

Compounds of formula I are described, their production and use in pharmaceutical agents.

Condensed 2,3-benzodiazepine derivatives and their use as AMPA-receptor inhibitors

The invention relates to new 1-[2-(substituted vinyl)]-3,4-dihydro-5H-2,3-benzodiazepine derivatives, a process for the preparation thereof and pharmaceutical compositions comprising them. The new 1-[2-(substituted vinyl)]-3,4-dihidro-5H-2,3-benzodiazepine derivatives according to the invention correspond to the general formula (I), ##STR1## wherein the variables are hereinbelow defined: The new compounds according to the invention affect the central nervous system and can be used to advantage in the therapy.

1-[2-(substituted vinyl)]-3,4-dihydro-4-dihydro-5H-2,3-benzodiazepine

This invention relates to new 1-�2-(substituted vinyl)!-5H-2,3-benzodiazepine derivatives, a process for the preparation thereof, pharmaceutical compositions comprising the same, to the use of the said benzodiazepine derivatives for the treatment of diseases and for the preparation of pharmaceutical compositions suitable for the treatment of diseases. The compounds according to the invention correspond to the general formula (I), ##STR1## wherein the variables are herein below defined, and the compounds possess central nervous activities.

1-�2-(substituted vinyl)!-5H-2,3-benzodiazepine derivatives

An N-benzoylamino acid compound of the formula (I), ##STR1## wherein R.sup.3 is an NR.sup.4 R.sup.5 group where R.sup.4 and R.sup.5 which are the same or different are selected from the group consisting of hydrogen, a hydroxyl group, a C.sub.1-12 alkyl group, a C.sub.1-4 alkyl group substituted by a hydroxyl group and a C.sub.1-4 alkyl group substituted by an amino group;

N-benzoylamino acid derivatives, pharmaceutical compositions containing

Derivatives of 2,3-benzodiazepine are substituted by one or two halogen atom(s) and have the general formula ##STR1## These derivatives are non-competitive AMPA antagonists and are used in pharmaceutical compositions. A process to make the 2,3-benzodiazepine derivatives includes converting starting compounds which are substituted by one or two halogen groups and have the general formula ##STR2##

2,3-Benzodiazepine Derivatives as non-competitive AMPA

3-substituted 3H-2, 3-benzodiazepine derivatives, the production and use

The invention relates to novel N-benzoylamino acid derivatives of the general formula (I), ##STR1## wherein R.sup.1 and R.sup.2, which are the same or different, stand for a hydroxyl group optionally bearing an acetyl group; or a C.sub.1-6 alkoxy group optionally substituted by a phenyl group;

N-benzoyl amino acid derivatives pharmaceutical compositions containing

The invention relates to novel N-acyl-2,3-benzodiezapine derivatives of the general formula (I), their stereoisomers and acid-addition salts, pharmaceutical compositions containing them and a process for their preparation. In the general formula (I)

N-acyl-2,3-benzodiazepine derivatives for treating acute and chronic

N-acyl-2,3-benzodiazepine derivatives pharmaceutical compositions

The invention relates to novel N-acyl-2,3-benzodiezapine derivatives and a method of treating spasms of the skeletal musculature therewith.

N-acyl-2,3-benzodiazepine derivatives and a method of treating spasms of

N-acyl-2,3-benzoidazepine derivatives, pharmaceutical compositions

The invention relates to novel N-acyl-2,3-benzodiezapine derivatives of the general formula (I), their stereoisomers and acid-addition salts, pharmaceutical compositions containing them and a process for their preparation. In the general formula (I), defined in the specification, a more complete description of the compounds may be found. The compounds of the general formula (I) possess valuable central nervous system effects, particularly muscle-relaxant, anticonvulsive and neuroprotective action. Thus, they may be useful for the treatment of various diseases of central nervous system origin.

N-acyl-2,3-benzodiazepine derivatives, pharmaceutical compositions

This invention relates to novel compounds of the general formula (I) and the pharmaceutically acceptable acid addition salts thereof. In the general formula (I) ##STR1## wherein Lip, A.sup.1, A.sup.2, Het and n are defined as in the specification. The compounds of the general formula (I) inhibit the lipid peroxidation and therefore, they are useful for the treatment or prevention of diseases and conditions wherein the inhibition of lipid peroxidation is desirable.

Piperazine and homopiperazine derivatives, pharmaceutical compositions

The invention relates to the new 1-(3-chlorophenyl)-4-hydroxymethyl-7,8-dimethoxy-5H-2,3-benzodiazepine of formula (I) ##STR1## and pharmaceutically acceptable acid addition salts thereof, furthermore to a process for preparing these compounds. The compounds according to the invention possess valuable anxiolytic, antiaggressive and antidepressant effects and have at the same time favorable acute toxicity values, so they can be used to advantage in therapy.

5H-benzodiazepin derivative

Growing community of inventors

Budapest, Hungary

Ferenc Andrasi